Advertisement

Topics

Norgine Company Profile

22:10 EST 16th December 2018 | BioPortfolio

Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. We have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders.

Location

Chaplin HouseWidewater Place
Moorhall Road
Harefield
Middlesex
UB9 6NS
United Kingdom

Contact

Phone: 44 1895 453710
Fax: 44 1895 453711


News Articles [20 Associated News Articles listed on BioPortfolio]

Norgine ouvre de nouveaux bureaux à Wettenberg en Allemagne

AMSTERDAM, July 20, 2018 /PRNewswire/ -- Norgine poursuit ses investissements en vue de soutenir sa stratégie de croissance L'Allemagne est le plus grand marché de Read more...

Norgine launches Shield’s Feraccru in the UK

Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.

Norgine buys rights to sell Shield’s iron deficiency therapy

Norgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand.

Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market

Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved...  

Norgine B.V. veräußert kanadische Anlagen aus dem Erwerb von Merus Labs International Inc. an Searchlight Pharma

Amsterdam und Montreal (ots/PRNewswire) - - Norgine erwarb Merus Labs International Inc. im Juli 2017 und wird alle Anlagen außerhalb von Kanada behalten - Searchlight Pharma wird mit sofortiger Wi.....

Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes ...

Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes ...

Norgine to commercialize Shield’s iron deficiency therapy in Europe, Australia and New Zealand

Under the terms of the agreement, Shield will receive an immediate £11 million upfront payment, is eligible to receive up to €4.5m in short-term development milestones and up The post Norgine to c...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Sensory Properties of Bowel Cleansing Solutions

Samples of 4 commercially available bowel cleansing solutions, namely PEG-electrolyte + ascorbic acid (PEG-Asc, Moviprep®, Norgine, UK), PEG-electrolyte (PEG, Fortrans® Ibsen, France), s...

Companies [0 Results]

None

More Information about "Norgine" on BioPortfolio

We have published hundreds of Norgine news stories on BioPortfolio along with dozens of Norgine Clinical Trials and PubMed Articles about Norgine for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Norgine Companies in our database. You can also find out about relevant Norgine Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record